Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Trifluoperazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 3/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 3/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 3/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 2/20 | 0.80 |
| ▸ | LMNA | P02545 | 7/20 | 1.00 |
| ▸ | MAPT | P10636 | 7/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 5/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 1.00 |
| ▸ | TP53 | P04637 | 4/20 | 1.00 |
| ▸ | USP2 | O75604 | 4/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | GMNN | O75496 | 2/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 2/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoperazine SCHEMBL23039392 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL29579627 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL29430171 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL41194 | 1.00 | LMNA (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL1897003 | 0.99 | FPR2 (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL29603012 | 0.99 | FPR2 (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL24866 | 0.99 | FPR2 (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL466955 | 0.97 | FPR2 (0.96) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| SCHEMBL21445272 | 0.97 | FPR2 (1.00) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 | |
| Trifluoperazine SCHEMBL28329317 | 0.94 | FPR2 (0.90) | LMNAMAPTSMN1; SMN2CYP3A4MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120053460-A | Pharmaceutical composition for preventing or treating flavivirus infection | 雷莫内克斯生物制药有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-12295967-B2 | Pharmaceutical composition for prevention or treatment of flavivirus infection | LEMONEX INC. (KR) | 2025-05-13 | — | — | US | claimed |
| US-20250057819-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2025-02-20 | — | — | US | claimed |
| WO-2023115220-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | INSTITUT NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CA) | 2023-06-29 | — | — | WO | claimed |
| US-20210228607-A1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FLAVIVIRUS INFECTION | SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) | 2021-07-29 | — | — | US | claimed |
| CN-112040954-A | Pharmaceutical composition for preventing or treating flavivirus infection | 雷莫内克斯生物制药有限公司 | 2020-12-04 | — | — | CN | claimed |
| US-10821107-B2 | Inhibitors of the FKBP51 protein from a high-throughput drug screen and methods of use | UNIVERSITY OF SOUTH FLORIDA (US) | 2020-11-03 | — | — | US | claimed |
| EP-3513782-A1 | GEL FORMULATIONS FOR ORAL ADMINISTRATION OF DRUGS, IN PARTICULAR TO DYSPHAGIC PATIENTS | Universita' Degli Studi Di Camerino (IT) | 2019-07-24 | — | — | EP | claimed |
| US-20190083455-A1 | METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-03-21 | — | — | US | claimed |
| US-20170105964-A1 | METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2017-04-20 | — | — | US | claimed |
| WO-2015195894-A1 | METHODS AND COMPOSITIONS FOR THE MODULATION OF BETA-ENDORPHIN LEVELS | THE GENERAL HOSPITAL CORPORATION (US) | 2015-12-23 | — | — | WO | claimed |
| US-20110224141-A1 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2011-09-15 | — | — | US | claimed |
| WO-2009148623-A2 | METHODS AND RELATED COMPOSITIONS FOR THE TREATMENT OF CANCER | STC.UNM (US) | 2009-12-10 | — | — | WO | claimed |
| EP-1583541-A2 | COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS | Neuronova AB (SE) | 2005-10-12 | — | — | EP | claimed |
| US-20050009847-A1 | Compounds and methods for increasing neurogenesis | NEURONOVA AB (COMPANY REGISTRATION NO. 556703-0118) (SE) | 2005-01-13 | — | — | US | claimed |
| WO-2004045592-A2 | COMPOUNDS AND METHODS FOR INCREASING NEUROGENESIS | NEURONOVA AB (SE) | 2004-06-03 | — | — | WO | claimed |
| US-20040029872-A1 | Inhibition of psychostimulant-induced and nicotine-induced craving | THE GENERAL HOSPITAL CORPORATION, A MASSACHUSETTS CORPORATION | 2004-02-12 | — | — | US | claimed |
| US-6517812-B1 | D1-like agonists or antagonists; SCH 23390 | THE GENERAL HOSPITAL CORPORATION | 2003-02-11 | — | — | US | claimed |
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | ERESINA LLC (US) | 2026-04-16 | — | — | US | disclosed |
| EP-0168626-A1 | Composition for the manufacture of a medicament for the therapeutic treatment of trauma of the skin | BAR-ILAN UNIVERSITY (IL) | 1986-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260102359-A1 | COMBINATION TREATMENT OF DERMAL AND TRANSDERMAL FIBROTIC DISEASES, DISORDERS AND ASSOCIATED PAIN AND INFLAMMATION | COL2A1, COLGALT1, PLOD3 | DRD2 4171/4885HTR2A 1608/4885HTR2C 1410/4885 |
| US-20250057819-A1 | DRUG COMBINATIONS FOR INHIBITING CORONAVIRUS REPLICATION | MME, ACE, ACE2 | DRD2 100/4885HTR2A 276/4885HTR2C 64/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.